Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18508042 | 0.80 | PLA2G1B (0.33) | PLA2G1BPLA2G2A | |
| SCHEMBL11964793 | 0.80 | — | — | |
| SCHEMBL19103232 | 0.78 | PIK3CD (0.35) | — | |
| SCHEMBL19325500 | 0.77 | THRB (0.31) | — | |
| SCHEMBL13986705 | 0.77 | — | — | |
| SCHEMBL18508052 | 0.75 | PLA2G1B (0.42) | PLA2G1BPLA2G2A | |
| SCHEMBL17753552 | 0.75 | — | — | |
| SCHEMBL17753551 | 0.75 | — | — | |
| SCHEMBL13986671 | 0.75 | — | — | |
| SCHEMBL18507946 | 0.70 | SCN1A (0.33) | PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | PLA2G1B 1858/4885PLA2G2A 1637/4885 |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | PLA2G1B 1858/4885PLA2G2A 1637/4885 |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | PLA2G1B 1858/4885PLA2G2A 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.